Key facts
- This page summarizes William R. Elder's Form 4 filing for Diffusion Pharmaceuticals Inc. (CRVO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Apr 2022, 17:17.
William R. Elder - 18 Apr 2022 Form 4 Insider Report for Diffusion Pharmaceuticals Inc. (CRVO)
- Reporting relationship
- GC & Secretary
- Issuer ticker
- CRVO
- Reported as of
- 18 Apr 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Apr 2022, 17:17:57 UTC
- Prior SEC filing
- 22 Mar 2022
- Next SEC filing
- 15 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ William R. Elder
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
William R. Elder filed Form 4 for Diffusion Pharmaceuticals Inc. (CRVO) on 19 Apr 2022.
Change
- Previous filing in this sequence was filed on 22 Mar 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DFFN
transaction
Common Stock
Conversion of derivative security
- Transaction value
- $2,500
- Shares
- +100
- Change %
- +33%
- Price
- $25.00*
- Shares after
- 400
- Date
- 18 Apr 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DFFN
transaction
Derivative
Series C Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $2,500
- Shares
- -100
- Change %
- -100%
- Price
- $25.00*
- Shares after
- 0
- Date
- 18 Apr 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100
- Exercise price
- $25.00
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
As previously announced, on March 18, 2022, the Reporting Person purchased 100 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Series C Shares"), from the Issuer at a purchase price of $25.00 per Series C Share in a private placement. On April 18, 2022, in accordance with Section 8(a) of the Certificate of Designation of Preferences, Rights, and Limitations of the Series C Convertible Preferred Stock (the "Certificate of Designation"), the Issuer delivered to the Reporting Person written notice of the Mandatory Conversion (as defined in the Certificate of Designations) of all outstanding Series C Shares into an equivalent number of shares of the Company's common stock, par value $0.001, pursuant to and in accordance with the terms of the Certificate of Designation.
Footnote F2
All share and per share amounts have been adjusted to reflect the Issuer's 1-for-50 reverse stock split, effective April 18, 2022.